Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Enhanced Vascular Function Following Intake of Feruloyl Esterase-processed High Fibre Bread.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03946293
Recruitment Status : Completed
First Posted : May 10, 2019
Last Update Posted : May 10, 2019
Sponsor:
Collaborator:
Biotechnology and Biological Sciences Research Council
Information provided by (Responsible Party):
Jeremy Paul Edward Spencer, University of Reading

Brief Summary:
This study evaluates the impact of a high phenolic acid intake from wholegrain wheat bread on human vascular function and plasma phenolic acid concentrations in healthy adults. All participants received a high fibre flatbread with enzymatically released free FA (14.22 mg), an equivalent standard high fibre bread (2.34 mg), or a white bread control (0.48 mg).

Condition or disease Intervention/treatment Phase
Cardiovascular Risk Factor Dietary Supplement: White Bread Dietary Supplement: Wholegrain bread Dietary Supplement: Wholegrain Enzyme Not Applicable

Detailed Description:

Clinical trial data have indicated an association between wholegrain consumption and a reduction in surrogate markers of cardiovascular disease. A number of components of wheat have been suggested to contribute to the cardiovascular health benefits associated with wholegrain consumption, most notably the fiber component. However, phenolic compounds that are bound to arabinoxylan fibre, particularly the hydroxycinnamate ferulic acid, may also contribute, in part, to vascular health effects. These phenolics may be more active when released enzymatically from the fiber prior to ingestion.

The aim of the present study was therefore to determine whether the intake of high fibre bread containing higher free ferulic acid levels (enzymatically released during processing) enhances human endothelium-dependent vascular function to a greater extent than that of traditional wholegrain bread and/or a white bread control.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 19 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Prevention
Official Title: Increased Bioavailability of Phenolic Acids and Enhanced Vascular Function Following Intake of Feruloyl Esterase-processed High Fibre Bread: a Randomized, Controlled, Single Blind, Crossover Human Intervention Trial.
Actual Study Start Date : January 5, 2015
Actual Primary Completion Date : June 30, 2015
Actual Study Completion Date : November 15, 2015

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Dietary Fiber

Arm Intervention/treatment
Active Comparator: White bread
White bread 3 x 30 g, single serving
Dietary Supplement: White Bread
White bread made with commercial white flour with bran/fibre removed

Active Comparator: Wholegrain
Standard wholegrain, 3 x 30 g, single serving
Dietary Supplement: Wholegrain bread
Wholegrain bread made with commercial wholegrain flour.

Experimental: Wholegrain Enzyme
Enzyme-treated wholegrain, 3 x 30 g, single serving
Dietary Supplement: Wholegrain Enzyme
Wholegrain bread made with enzyme-treated commercial wholegrain flour.




Primary Outcome Measures :
  1. Flow-mediated dilatation (FMD) [ Time Frame: Change from baseline to 5 hours ]
    FMD of the brachial artery


Secondary Outcome Measures :
  1. Plasma phenolic acids [ Time Frame: Change from baseline to 24 hours ]
    Presence of phenolic acid metabolites in the circulation over a 24 h period.

  2. Laser Doppler Imaging with iontophoresis [ Time Frame: Change from baseline to 5 hours ]
    Laser Doppler Imaging with iontophoresis (acetyl choline and sodium nitroprusside)

  3. Digital Volume Pulse (DVP) [ Time Frame: Change from baseline to 5 hours ]
    DVP stiffness index (DVP-SI) and DVP reflexion index (DVP-RI)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   20 Years to 55 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

1) fasting lipids in the upper half of the normal range (triacylglycerol 0.8-3.2 mmol/l and total cholesterol 6.0-8.0 mmol/l); 2) BMI 25-32 kg/m2; 3) non-smoker; 4) not diabetic (diagnosed or fasting glucose < 7 mmol/l) or suffer from endocrine disorders; 5) hemoglobin and liver enzymes levels within the normal range [Alanine Transaminase (ALT): 0-55 IU/L; Alkaline Phosphatase (ALP): 38-126 U/L; Aspartate Transaminase (AST): 0-45 IU/L; Gamma Glutamyl Transferase (GGT): 12-58 IU/L]); 6) not having suffered a myocardial infarction/stroke in the past 12 months; 7) not suffering from renal or bowel disease or have a history of choleostatic liver or pancreatitis; 8) not on drug treatment for hyperlipidemia, hypertension, inflammation or hyper-coagulation; 9) not taking any fish oil, fatty acid or vitamin and mineral supplements; 10) no history of alcohol misuse; 11) not planning, or on a weight reduction regime; 12) not having taken antibiotics in the 6 months prior to the study; and 13) being able to consume the study interventions.

Exclusion Criteria:

  • Gluten sensitive

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03946293


Locations
Layout table for location information
United Kingdom
Department of Food and Nutritional Sciences
Reading, Berkshire, United Kingdom, RG6 6AP
Sponsors and Collaborators
University of Reading
Biotechnology and Biological Sciences Research Council
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Jeremy Paul Edward Spencer, Professor of Nutritional Medicine, University of Reading
ClinicalTrials.gov Identifier: NCT03946293    
Other Study ID Numbers: Wholegrain_FMD
First Posted: May 10, 2019    Key Record Dates
Last Update Posted: May 10, 2019
Last Verified: May 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No